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Abstract
Amyotrophic lateral sclerosis, or Lou Gehrig’s disease, is characterized by motor neuron death, 
with average survival times of two to five years. One cause of this disease is the misfolding of 
superoxide dismutase 1 (SOD1), a phenomenon influenced by point mutations spanning the 
protein. Herein, we used an epitope-specific high-throughput screen to identify a peptide ligand 
that stabilizes the SOD1 native conformation and accelerates its folding by a factor of 2.5. This 
strategy may be useful for fundamental studies of protein energy landscapes as well as designing 
new classes of therapeutics.
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Superoxide dismutase 1 (SOD1) is a cytosolic protein that mitigates oxidative stress by 
converting O2•−into H2O2 and O2. While the wild type (WT) structure is highly stable with 
denaturation at approximately 95°C, destabilizing point mutations increase its propensity to 
misfold and aggregate, ultimately leading to amyotrophic lateral sclerosis (ALS).[1–5] ALS 
is characterized by motor neuron death,[6] with a survival time of two to five years after 
diagnosis and only two FDA-approved treatments with marginal benefit.[7] Over 160 point 
mutations spanning 90 residues on SOD1 are linked to ALS,[8] complicating the 
development of general therapeutics that address its misfolding.[9] In vitro studies indicate 
that both the unfolded and native states lie on the aggregation pathway,[2,4] suggesting that 
stabilizing the ground-state structure while accelerating folding might address underlying 
disease mechanisms.[10,11] Epitope-specific antibodies and their antigen-recognition regions 
as well as overexpressed heat shock proteins[12] have shown some therapeutic benefit in 
ALS mouse models.[3,11,13] Small molecules identified in cell-based screens have also 
mitigated toxicity from SOD1 aggregation in preclinical studies, yet their biological targets 
remain unknown.[14] We sought to combine the advantages of these approaches by exploring 
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the small-molecule-targeted stabilization of key SOD1 epitopes so as to modify its folding 
energy landscape by stabilizing its folded structure while accelerating its folding.
To perform in these roles, the ligands must bind the folded ground-state structure and 
stabilize the rate-limiting transition state. We focused on the electrostatic loop (amino acids 
121–144; Figure 1a, red), which is a target relevant to both functions. Studies of ALS-
causing mutants by NMR spectroscopy,[15,16] H/D exchange,[15,17] and high-resolution X-
ray diffraction[18–21] indicate consistent destabilization of this loop when even distant 
mutations are present.[3] Investigations into the relative impact of point mutations on the 
folding rate and protein stability[22] highlight the importance of this region for the rate-
limiting transition state.[23,24] Ligands binding to the loop might accelerate folding while 
mitigating the effects of mutations on the ground-state structure (Figure 1b).
To identify such ligands, we employed an in situ click screen that furnishes epitope-specific 
peptides.[25] A peptide containing amino acids 121–141 representing the electrostatic loop 
was synthesized with a Leu126 | propargyl glycine substitution and a C-terminal biotin assay 
handle (Figure 1a), and subsequently incubated with a one-bead-one-compound library of 
cyclic peptides bearing N-terminal azides. For this in situ click screen, library members that 
bind the target epitope induce a dipolar cycloaddition between the azide and alkyne (without 
CuI), decorating hit beads with biotin. Through tandem molecular recognition and enzymatic 
amplification, these hits were identified and sequenced by Edman degradation.
The screen yielded hits with observable similarity (see the Supporting Information, Figure 
S2), which were tested for binding against the full-length protein (Figure S4). The ligand 
with the best binding affinity, containing the variable region sequence HGG4FFQ (4FF = 4-
fluorophenylalanine) (Figure 2), bound the metalated (holo) protein with EC50 = 8.0 μm 
(Figure S6) and the non-metalated (apo) protein with EC50 = 0.94 μm (Figure S7). This 
binding difference may be due to the increased disorder of the electrostatic loop in the apo 
form, which more closely resembles the conformations adopted by the synthetic epitope. 
The peptide also bound three ALS-causing mutants containing destabilized electro-static 
loops, G85R, D90A, and G93A, with similar affinities (Figure S8). 1H–15N HSQC NMR 
spectroscopy confirmed selective binding of the peptide to the electrostatic loop on both the 
holo (Figure 3 and Figures S12–S15) and apo (Figures S16–S20) variants. Statistical 
analysis of these spectra revealed that equimolar concentrations of ligand with holo SOD1 
caused resonances associated with the loop to either change intensity, shift, or disappear 
altogether. At increased ligand concentrations, additional residues near the loop and at the 
dimer interface were shifted. Connolly maps of SOD1 revealed that those residues at the 
dimer interface are not solvent-exposed, and so perturbations in this region are likely 
allosteric effects.[26] For apo SOD1, perturbations at 1 equiv were similar to those observed 
at 2 equiv with holo SOD1, which is consistent with the expected occupancy of HGG4FFQ 
on each protein variant (Figure S20).
We employed dynamic light scattering (DLS) analysis to gain insight into the effects of 
binding to the electrostatic loop. The hydrodynamic radius (rh) of apo WT SOD1 decreased 
with the addition of HGG4FFQ from 3.68 ± 0.26 nm to 2.88 ± 0.07 nm (Figure 4). The 
resulting complex was smaller than the holo WT protein (3.32 ± 13 nm), suggesting that 
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ligand binding induces a tightening of the peripheral structure of the protein, which is 
disordered without metal (Figure S21a). Higher-amplitude structural fluctuations were also 
observed in the absence of ligand (Figure S21b). Thus ligation both reduced the rh of apo 
SOD1 and narrowed the width of those fluctuations (Figure 4). Similar size decreases were 
not observed with holo WT SOD1 (Figures S21, S22, and S29), implying that the more 
stabilized variant is less affected by ligand binding. These observations are consistent with 
1H–15N HSQC spectra, where ligand titration perturbed a narrow band of residues that 
intersects the z axis of the β-barrel. With increasing HGG4FFQ concentration, the peak 
intensities across the spectrum increased, indicating reduced conformational freedom along 
the amide backbone of the protein. Ligand-induced decreases in rh were also observed with 
G93A and D90A (Figure S23) SOD1. Apo G93A was larger than WT (4.27 ± 0.40 nm), 
which highlights its more destabilized structure.[27] Notably, ligand binding to this mutant 
reduced its rh to match the WT structure (3.04 ± 0.19 nm). An additional impurity at higher 
rh deriving from HGG4FFQ was also observed in DLS traces (Figure S24). Because of the 
sharply increased light scattering intensity with an increasing hydrodynamic radius (I α rh6), 
this peak represents less than 0.01% of these samples/. No additional species were observed 
in these mixtures by SEC-UV and 1H/19F NMR analysis (see the Supporting Information 
and Figures S10, S11, and S24–S29); we therefore conclude that this low-abundance 
impurity is not involved with the phenomena described here. These measurements indicate 
that binding the electrostatic loop stabilizes the hydrodynamic structure of apo WT SOD1 
and its mutants through allosteric interactions connecting the electrostatic loop and the β-
barrel.
To understand the impact of ligand binding on the rate-limiting transition state of folding, 
we generated a chevron plot for SOD1 (Figure 5).[28] Here, the folding (kf) and unfolding 
(ku) rates were plotted against [GdmCl], generating a characteristic V-shaped plot where 
extrapolation to the intercept furnishes the rates at zero denaturant concentration (kf,0 and 
ku,0). A mutant whose surface cysteines were removed (pWT, C6A/C111S) was employed in 
its apo form for these studies. SOD1 contains one Trp on each monomer (and no Tyr), 
enabling this measurement by monitoring changes in fluorescence (Figure S31).[29] The 
protein was first denatured with GdmCl and then diluted in buffer containing the ligand 
(Figure S29). We found consistent folding rate increases across a range of GdmCl 
concentrations. Notably, the slopes of ln(kf) versus [GdmCl] were similar with (mf,L = 
−2.74) and without (mf = @2.52) ligand, indicating that the basic rate-limiting transition 
state remains unchanged. Extrapolation to [GdmCl] = 0m revealed a 2.5-fold increase in the 
folding rate with ligand (p < 0.005). At [GdmCl] >1.5m, we measured the unfolding rate 
with Trp fluorescence by adding denaturant directly to the folded protein (Figure S29). 
Unfolding in the absence of ligand also revealed a linear relationship between ln(ku) and 
[GdmCl], where ku,0 was reduced by a factor of 1.2 in the presence of ligand; however, this 
difference was not statistically significant (p <0.20). Knowledge of kf,0 and ku,0 yields the 
Keq and ΔG values of folding (Table S2). In the absence of ligand, ΔGf = −2.84 kcal mol−1, 
which drops to ΔGf = −3.49 kcal mol−1 upon HGG4FFQ binding. Comparing the change in 
ΔG for the folded (ΔΔGf) and transition-state (ΔΔG≠) structures reveals that nearly 80% of 
the stability imparted by HGG4FFQ derives from an increasing kf value as opposed to a 
reducing ku value, the latter of which is more common for pharmacological chaperones.[30] 
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Moreover, this acceleration represents only a fraction of the overall binding energy available 
from the ligand (for KD = 8.01 μm, ΔG =−6.95 kcal mol−1). In preliminary experiments, this 
phenomenon was also observed with pG93A SOD1, where HGG4FFQ accelerated folding 
by a factor of 1.5 at [GdmCl] = 0.5m (Figure S23). The relatively smaller influence on this 
mutant might derive from increased destabilization of the electro-static loop upon mutation. 
Overall, increasing kf,0 without perturbing ku,0 indicates that targeting the electrostatic loop 
lowers the barrier to folding with concomitant stabilization of the native state.
In conclusion, we have developed a targeted ligand designed to modulate the folding energy 
landscape of SOD1. The cyclic peptide HGG4FFQ stabilizes and tightens the ground-state 
structure, while also accelerating folding by reducing the activation barrier to the native 
state. Even with a modest binding affinity, its influence on the folding rate is significant. The 
majority of chaperones function as holdases, preventing off-pathway aggregation, rather than 
as foldases, which accelerate folding. Foldases, which are both ATP-dependent and -
independent, exhibit a range of rate enhancements from 1.5 to 50.[31] In this work, a peptide 
that is one to two orders of magnitude smaller than these chaperones improved the folding 
rate by a factor of 2.5. We speculate that the outsized impact of HGG4FFQ derives from its 
targeted recognition of the electrostatic loop, a key component of the SOD1 folding 
trajectory. An open question is the function of these types of stabilizing ligands within more 
complex environments. Chaperones in vivo operate in high concentrations of adventitious 
protein, and we intend to leverage the molecularity of these reagents to understand how 
folding rates might be engineered in these settings.
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Figure 1. 
a) SOD1 is a C2-symmetric dimer with a copper active site (blue) and a zinc cofactor (gray). 
The electrostatic loop (red) is destabilized across several ALS-causing mutations, including 
G85R (green), D90A (purple), and G93A (orange). b) The apo protein exhibits two-state 
folding, with fast dimerization relative to folding (PDB No. 2V0A).
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Figure 2. 
The HGG4FFQ peptide macrocycle ligand from the in situ click screen against the 
synthesized electrostatic loop epitope of SOD1.
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Figure 3. 
a) 1H–15N HSQC NMR spectroscopy on holo WT SOD1 with HGG4FQ reveals localized 
binding around the electrostatic loop (red square) at 1 equiv ligand. b) Additional residues 
are perturbed at 2 equiv HGG4FFQ through allosteric effects. Ligand equivalents are relative 
to the monomer subunit.
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Figure 4. 
Decreases in the hydrodynamic radius of apo WT SOD1 (rh) are observed in the presence of 
HGG4FFQ. The distribution of these values also narrows with addition of ligand (n =54).
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Figure 5. 
Folding rate constants for apo WT SOD1, combined into a chevron plot, reveal an 
enhancement in the folding rate in the presence of ligand by a factor of 2.48, without 
changing the rate-limiting transition structure (p <0.005).
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